ArticleOncology letters2026
Efficacy and safety of blinatumomab combination therapy in high-risk B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to evaluate the efficacy and safety of blinatumomab-based combination therapy for high-risk B-cell acute lymphoblastic leukemia (B-ALL). PubMed, Embase, Web of Science and the Cochrane Library were searched for clinical studies on blinatumomab. The primary endpoints were complete remission (CR), minimal residual disease (MRD) and complete molecular remission (CMR). The secondary endpoint was overall survival (OS). Safety outcomes included adverse events (AEs), cytokine release syndrome, neurological events and hematological toxicity. A total of 11 studies involving 402 patients were included. The pooled CR rate was 87% (95% CI, 78-95%), the MRD negativity rate was 81% (95% CI, 75-87%) and the CMR rate was 81% (95% CI, 69-92%). The 1-year OS rate was 91% (95% CI, 78-100%), the 2-year OS rate was 87% (95% CI, 71-100%) and the 3-year OS rate was 52% (95% CI, 36-66%). Regarding safety, 86% (95% CI, 77-96%) of patients experienced all-grade AEs. Grade ≥3 AEs were generally consistent with known safety profiles, with the most common events being neutropenia (38%; 95% CI, 0-84%), febrile neutropenia (26%; 95% CI, 10-43%), and hyperglycemia (21%; 95% CI, 5-36%). In conclusion, blinatumomab-based combination therapy is an effective treatment for high-risk B-ALL with manageable toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.